Seven Dutch citizens have brought allegations of extraordinary gravity against some of the world's most influential political and pharmaceutical figures. Their case asks whether the COVID-19 vaccination programme involved not merely errors of judgment, but deliberate wrongdoing on an international scale. As the proceedings reach a substantive hearing, the documents demand examination, not because the allegations have been proved, but because the distinction between an allegation and a finding must ultimately be determined by evidence.
INR Report: Based on the civil proceedings before the District Court of Northern Netherlands, legal submissions by Peter W.H. Stassen, expert statements by Dr Mike Yeadon, Alexandra Latypova and Joseph Sansone, and financial research published by Catherine Austin Fitts.
On 22 October 2026, a courtroom in Leeuwarden, Netherlands, became the setting for a civil dispute whose allegations reach far beyond the injuries claimed by the people who brought it.
Among the defendants are Bill Gates, Pfizer chief executive Albert Bourla, former Dutch Prime Minister Mark Rutte and the Dutch State.
The seven original plaintiffs allege that they were deceived into accepting COVID-19 vaccinations and suffered serious harm as a result. Two have died since the proceedings began.
Their lawyer, Peter W.H. Stassen, has pursued the case since July 2023, assembling legal pleadings, documentary exhibits and statements from witnesses who challenge fundamental aspects of the pandemic response.
The District Court of Northern Netherlands confirmed the substantive civil hearing for 22 October.
The court's description of the plaintiffs' position is unusually stark. They allege that the defendants induced them to be vaccinated through deception, despite allegedly knowing that the injections were harmful. The plaintiffs also dispute the existence of the virus responsible for COVID-19, a position contradicted by extensive virological and clinical evidence.
This is not a criminal prosecution. It is a civil action seeking to establish liability and obtain compensation.
Yet the documents reveal that the plaintiffs are advancing a case much broader than conventional medical negligence.
They allege that pharmaceutical products were deliberately designed to cause harm, that emergency legal arrangements concealed their true nature, and that military and financial institutions helped coordinate a global programme presented to the public as a health emergency.
If intentional, coordinated harm against civilian populations were established through reliable evidence and judicial findings, the implications would be of extraordinary historical significance.
The question is whether the plaintiffs can prove it.
A Former Pfizer Executive Makes His Accusation
Among the most provocative documents is a statement dated 7 December 2025 by Dr Mike Yeadon.
Yeadon is a former Pfizer vice president and worldwide head of allergy and respiratory research. He left Pfizer in 2011 and subsequently founded a biotechnology company acquired by Novartis.
His professional background gives him experience in pharmaceutical research and drug development. It does not, by itself, establish the correctness of his conclusions.
In his submission, Yeadon alleges that the design of COVID-19 mRNA vaccines reveals deliberate intent to cause injury.
He writes:
"These molecules were designed intentionally to injure, kill and reduce fertility in survivors."
This is the central accusation of his statement.
Yeadon does not argue simply that manufacturers overlooked potential adverse reactions. He contends that features he considers dangerous were selected knowingly.
He identifies three principal concerns.
The first concerns immune responses against cells producing the protein encoded by the vaccine. The second concerns the selection of the coronavirus spike protein. The third concerns lipid nanoparticles used to deliver the mRNA, including questions about where those particles travel in the body.
Yeadon argues that these design choices indicate intentional toxicity.
His submission also alleges that the products were inadequately tested and improperly presented as conventional vaccines.
These are serious claims, but his reasoning does not establish that the products were designed to kill or cause infertility. The known possibility of adverse reactions does not, without further evidence, demonstrate deliberate intent to injure. Nor does the ability of a technology to produce harm establish that harm was its intended purpose.
Large clinical studies and post-authorisation research have found that COVID-19 vaccines reduced the risk of severe disease, while also identifying uncommon but sometimes serious adverse reactions.
Those findings directly challenge Yeadon's sweeping assertion that the products were inherently designed for harm.
Nevertheless, his submission raises questions that can be examined against manufacturing records, toxicology studies, safety monitoring and the knowledge available to regulators.
Yeadon also makes an explicit offer to the court:
"I am willing to answer any reasonable question and eager to give evidence under oath."
That willingness matters because the plaintiffs have disputed the court's decision not to hear their proposed experts orally during the October hearing.
A witness's confidence does not establish the truth of their evidence. Cross-examination, however, is one means by which claims can be tested.
The public interest lies in understanding which evidence was admitted, how it was challenged and how the court evaluates it.
Alexandra Latypova: Follow the Regulatory Trail
If Yeadon's submission addresses the alleged mechanism of harm, Alexandra Latypova's October 2026 statement attempts to explain how such products could have been developed, purchased and distributed.
Her 107-page submission is the most extensive of the newly supplied expert documents.
Latypova, who has a background in pharmaceutical research and development, focuses on the relationship between emergency countermeasure legislation, manufacturing regulation, government contracts and military procurement.
She alleges that COVID-19 mRNA products were presented as medicines while being developed and deployed through emergency arrangements associated with national security.
Her central contention is that the public was not adequately informed about the legal and regulatory framework governing the products.
She describes this as a regulatory "bait and switch."
The submission examines US emergency-use provisions, the Public Readiness and Emergency Preparedness Act, European regulatory arrangements, manufacturing inspections and contractual protections for manufacturers.
Latypova also discusses leaked European Medicines Agency material and later manufacturing inspection findings, arguing that they reveal problems that should have prevented the products from being distributed.
These are potentially important documentary leads.
Emergency authorisations, liability protections, defence procurement contracts and regulatory flexibility were real features of the pandemic response. But their existence does not establish that pharmaceutical safety law ceased to apply altogether, that vaccines were secretly classified as weapons or that manufacturers intended to harm recipients.
Those conclusions require additional evidence.
The distinction becomes especially important when Latypova turns to Operation Warp Speed, the US programme that accelerated vaccine development and distribution.
Military logistics and procurement played a substantial role in that programme.
Latypova interprets this involvement as evidence that the pandemic response was fundamentally a military operation rather than a public-health response.
That interpretation is contested.
Military involvement in emergency logistics can have an ordinary explanation: governments may use defence capabilities to coordinate large-scale production and distribution during national emergencies.
To establish Latypova's more serious allegation, it would be necessary to identify documentary evidence demonstrating an unlawful purpose, not merely military participation.
Her submission attempts to draw that connection through contracts, regulatory classifications and institutional relationships.
It is precisely here that the investigation must be most demanding.
Who signed the contracts? What did those contracts require? Which safety obligations remained enforceable? What did regulators know about manufacturing problems? And what evidence, if any, connects those decisions to deliberate harm?
These questions are capable of documentary examination.
They should be pursued without assuming that every irregularity proves a conspiracy or that every official explanation is sufficient.
Joseph Sansone and the Biological-Weapons Allegation
A separate affidavit by Joseph Sansone advances the plaintiffs' biological-weapons argument.
Sansone is a psychotherapist with qualifications in psychology and mental-health counselling. His submission addresses legal and psychological theories rather than presenting original pharmaceutical toxicology research.
He argues that COVID-19 mRNA injections should be treated as biological and technological weapons under US law and the Biological Weapons Convention.
His statement also relies on an affidavit attributed to the late international-law scholar Francis Boyle, who had argued that the products met the legal definition of biological weapons.
Sansone alleges that governments, pharmaceutical companies and media organisations concealed harmful effects.
His claims extend to reduced life expectancy, infertility, cancer, transmission of vaccine components to unvaccinated people and an alleged international depopulation programme.
These assertions are not established by the affidavit.
In particular, the submission's extrapolations from adverse-event reports and population statistics cannot be treated as reliable estimates of vaccine-caused deaths without validated causal analysis.
There is no established scientific evidence that COVID-19 vaccination has caused the sweeping population-level harms alleged, or that vaccinated people transmit vaccine technology to others in the manner Sansone describes.
His legal interpretation is also disputed. The existence of a technology with potential dual-use applications does not automatically make a particular medical product a biological weapon.
Intent, purpose, composition and actual use are critical distinctions.
Nevertheless, Sansone's affidavit makes clear the severity of the accusation the plaintiffs want examined.
They are not merely alleging that warnings were inadequate.
They are asking a civil court to consider whether products administered under a public-health programme were, in their view, instruments of intentional harm.
That is why the evidential standard matters so profoundly.
Catherine Austin Fitts: The Financial Dimension
The fourth strand of the plaintiffs' wider argument comes from Catherine Austin Fitts, a former US Assistant Secretary of Housing and Urban Development and financial analyst.
Her publication, The Going Direct Reset, was issued in 2021 and includes substantial analysis by attorney John Titus.
It examines monetary interventions beginning before the pandemic, particularly the US Federal Reserve's emergency lending operations and the relationship between central-bank policy, government spending and financial markets.
Fitts argues that the pandemic period accelerated a transformation of the monetary system, transferring power towards financial institutions and central authorities.
The report connects this argument to a broader theory of economic restructuring.
There are legitimate subjects for investigation here.
Central-bank intervention, emergency government expenditure, asset-price inflation and the distribution of economic benefits during the pandemic are matters of public record.
New Zealand experienced its own large-scale monetary and fiscal interventions, with lasting debate over their effects on housing prices, inflation, public debt and household purchasing power.
But evidence that powerful institutions benefited financially from pandemic policies does not, by itself, prove that those institutions engineered the pandemic or coordinated deliberate medical harm.
The financial thesis and the biological-weapons allegation must therefore be examined separately before any connection between them can be established.
For an independent investigation, the useful questions concern documented decisions and financial flows.
Who received government contracts?
How were risks and liabilities allocated?
Which companies benefited from procurement arrangements?
How did central-bank interventions affect wealth distribution?
And did the public receive a transparent account of the costs?
These questions remain relevant whether or not the plaintiffs' overarching theory succeeds.
The Courtroom Is Where Allegations Must Meet Evidence
The proceedings have already produced significant procedural disputes.
In October 2024, the Dutch court rejected Bill Gates' challenge to its jurisdiction.
That decision allowed the claim against him to continue. It did not establish wrongdoing.
The plaintiffs subsequently sought to have their proposed experts examined orally under oath.
The court declined that request for the October hearing, leading Stassen to arrange recorded testimony and make further submissions concerning the treatment of the evidence.
According to the plaintiffs' October 2026 press release, written expert material remained before the court.
This distinction is important.
A document submitted by a party is not automatically accepted as reliable expert evidence, and a court's decision to restrict oral testimony does not necessarily demonstrate unfairness.
Courts are responsible for managing proceedings, determining relevance and assessing admissibility.
At the same time, procedural fairness requires that parties have a meaningful opportunity to advance their case and answer the opposing side.
The Dutch court's eventual reasoning will therefore be important not only for what it concludes about liability, but for how it evaluates the competing scientific and legal arguments.
The 22 October hearing is not itself a finding that the allegations are true.
Nor should the existence of controversial allegations prevent accurate reporting of the proceedings.
The defendants are entitled to contest the claims, challenge the proposed experts and rely on the scientific and regulatory evidence supporting their positions.
The plaintiffs are entitled to pursue their claims within the applicable rules of civil procedure.
Justice requires that neither reputation nor suspicion substitute for proof.
Does This Affect New Zealand?
For New Zealand, the significance of the Dutch proceedings is not confined to the possibility of an eventual judgment overseas.
It lies in the questions they raise about the decisions made here.
New Zealand's COVID-19 response involved vaccine procurement, regulatory approvals, employment mandates, public-health restrictions and extraordinary government expenditure.
The decisions affected millions of people.
For some, vaccination was an ordinary medical choice. For others, employment requirements made refusal carry substantial economic consequences.
Some people subsequently experienced serious adverse reactions.
New Zealand's own ACC records recognise that qualifying COVID-19 vaccination-related treatment injuries occurred.
According to the July 2026 ACC claims refresh, 4,586 vaccination-related treatment injury claims had been lodged, with 1,797 accepted, 2,745 declined and 44 awaiting a decision.
The accepted claims included serious cardiac and other medical injuries, and six claims involving fatal injuries.
Payments on accepted claims totalled approximately NZ$18.38 million by July 2026.
These figures are important because they establish that vaccine-related harm is not merely an allegation made by critics of the pandemic response.
New Zealand's own statutory compensation system has accepted that some people suffered injuries caused by COVID-19 vaccination, including fatal injuries.
That does not mean every illness or death reported after vaccination was caused by it. It does not establish deliberate harm or validate the Dutch plaintiffs' allegations.
It does mean that the people whose injuries have been recognised deserve effective care, fair compensation and transparent decision-making.
Others who believe they were injured but whose claims were declined deserve access to proper review and an explanation grounded in medical evidence.
Claims involving aggressive cancers, sometimes described publicly as turbo cancers, require the same discipline. A cancer diagnosis after vaccination is not proof that vaccination caused it, and available evidence has not established a causal link between COVID-19 vaccines and accelerated cancer development.
Individual suffering should not be dismissed. Nor should unproven causal explanations be presented as established medical fact.
New Zealand's Royal Commission and the Accountability Gap
The second phase of New Zealand's Royal Commission of Inquiry into COVID-19 Lessons Learned was released in March 2026.
It examined vaccine approvals and safety, mandates, lockdowns and other major decisions.
The Commission received more than 31,000 submissions and reviewed thousands of documents.
It concluded that the pandemic response was, overall, reasonable in the circumstances, while identifying significant shortcomings.
Some restrictions remained in place longer than necessary.
Certain mandate decisions were made with less information than could have been available.
The consequences for employment, businesses, rights and social cohesion were not always adequately considered.
These findings deserve careful attention.
They also expose the difference between reviewing policy and determining individual responsibility.
The Royal Commission was not a civil court deciding whether a particular injured person was entitled to damages from a named decision-maker.
It was not a criminal investigation into alleged intentional harm.
Its principal task was to establish lessons for future emergencies.
Critics have characterised the inquiry as a whitewash, arguing that its conclusions did not deliver the accountability they sought.
That assessment is contested. The Commission did examine substantial evidence and criticise important aspects of government policy.
Yet the question of individual accountability cannot be answered simply by pointing to the completion of an inquiry.
If a government acknowledges that restrictions were maintained too long, what remedy is available to the worker who lost a career?
If a person suffers a recognised vaccine injury, is the compensation and rehabilitation provided sufficient?
If a regulatory decision is challenged, can citizens obtain the underlying evidence and understand how risks were assessed?
And if an official acted unlawfully, what mechanisms exist to establish responsibility?
These are questions of justice as much as public administration.
New Zealand's ACC system provides no-fault compensation for qualifying injuries, but generally restricts ordinary compensatory damages claims for covered personal injury.
That means a lawsuit resembling the Dutch proceedings cannot simply be reproduced under New Zealand law.
The legal differences make the adequacy of domestic remedies especially important.
Follow the Documents, Not the Assumptions
The Dutch submissions suggest a practical investigative agenda for New Zealand.
The relevant evidence would include Medsafe's regulatory assessments, manufacturing and quality information available to officials, government procurement agreements, indemnity arrangements, Cabinet papers, public-health advice and adverse-event monitoring records.
It would also include the changing scientific evidence about transmission, severe disease, vaccine effectiveness and adverse reactions.
The critical question is not whether officials possessed perfect knowledge at the beginning of the pandemic.
They did not.
It is whether decisions remained justified as knowledge changed, whether known risks were communicated adequately and whether people affected by those decisions had meaningful opportunities for review.
The same scrutiny should apply to the allegations made by the Dutch plaintiffs.
If there is evidence of unlawful conduct, it should be investigated and tested.
If a claim depends on a mistaken interpretation of a regulation, contract or scientific study, that should be exposed just as clearly.
If a person suffered a genuine injury, their experience should not be erased by a debate about the broader vaccination programme.
And if allegations of deliberate wrongdoing cannot be substantiated, that conclusion must also be reported.
Will this in fact make New Zealand stronger?
It will, if the examination produces more transparent institutions, stronger safeguards for medical consent, effective injury support, better emergency decision-making and genuine accountability where wrongdoing is established.
Those outcomes do not require acceptance of a global conspiracy theory.
They require a willingness to confront the documentary record.
Truth, Justice and the Responsibility to Investigate
The Netherlands Case presents an extraordinary set of allegations.
A former pharmaceutical executive alleges intentional product design to cause harm.
A pharmaceutical-industry researcher alleges regulatory deception and military coordination.
A psychotherapist advances a biological-weapons interpretation.
A financial analyst argues that the pandemic response formed part of a wider monetary and institutional restructuring.
Together, these submissions present the plaintiffs' theory of deliberate, coordinated wrongdoing.
But their existence does not prove that theory.
The court must determine what evidence is reliable, whether the alleged conduct occurred, whether the named defendants bear legal responsibility and whether the plaintiffs' injuries can be causally connected to that conduct.
The difference between a catastrophic mistake and an intentional crime is not rhetorical. It is a distinction requiring evidence of knowledge, conduct and intent.
The stakes are considerable precisely because the allegations are so grave.
A judicial finding of deliberate, coordinated harm would demand profound international scrutiny. A rejection of the claims would also require accurate reporting, including the reasons the court found the evidence insufficient.
For New Zealand, the duty to examine its own pandemic record remains regardless of the outcome.
The country has documented vaccine injuries.
Its Royal Commission has identified policy shortcomings.
Its citizens have experienced lasting health, financial and social consequences from both the disease and the measures adopted in response.
Those facts are enough to justify continuing public examination of what happened.
Truth cannot be established by protecting powerful people from questions. But neither can it be established by treating accusations as convictions.
Justice requires evidence, fair procedures, transparent decisions and effective remedies.
Accountability requires identifying who made decisions, what they knew, what obligations they carried and whether those obligations were met.
And for those who suffered genuine harm, justice must mean more than becoming a statistic in a report.
The Netherlands proceedings have placed extraordinary allegations before a court.
New Zealand must decide, through its own legal and democratic institutions, how fully it is prepared to examine its own record.
An inquiry may have ended. The responsibility to answer legitimate questions has not.
Sources
- The Netherlands Case: Official Case Archive
- District Court of Northern Netherlands: Substantive Hearing Announcement, September 2026
- The Netherlands Case: How Did the Case Get Here?
- Dr Mike Yeadon, Expert Statement, 7 December 2025, supplied court submission.
- Alexandra Latypova, Expert Witness Statement, updated October 2026, supplied court submission.
- Joseph Sansone, Affidavit, supplied court submission.
- Catherine Austin Fitts and contributors, The Going Direct Reset, The Solari Report, 2021, supplied publication.
- Peter W.H. Stassen, Deed of 22 September 2026, supplied legal submission.
- The Netherlands Case, Official Press Release, 21 October 2026, supplied document.
- ACC: COVID-19 Vaccination Claims Refresh, July 2026
- Royal Commission of Inquiry: Phase Two Report
- Royal Commission: Summary of Findings
- New Zealand Government Response to the Royal Commission, July 2026
Independent reporting. Original context. Credited sources.